An Open Label, Single Arm, Multiple Dose Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of LNP023 When Administered in Addition to Standard of Care (SoC) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs LNP-023 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 29 Oct 2019 Planned End Date changed from 23 Feb 2023 to 16 Mar 2023.
- 18 Aug 2019 Planned End Date changed from 13 Apr 2023 to 23 Feb 2023.
- 08 Aug 2019 Planned primary completion date changed from 11 Jul 2019 to 10 Jan 2020.